BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16225511)

  • 1. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.
    Gontero P; Marini L; Frea B
    BJU Int; 2005 Nov; 96(7):970-6. PubMed ID: 16225511
    [No Abstract]   [Full Text] [Related]  

  • 2. Gemcitabine in bladder cancer.
    El Karak F; Flechon A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3251-6. PubMed ID: 18035967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.
    De Berardinis E; Antonini G; Peters GJ; Loves WJ; Van der Born K; Codacci-Pisanelli G; Di Silverio F
    BJU Int; 2004 Mar; 93(4):491-4. PubMed ID: 15008715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Toxicity of intravesical gemcitabine in superficial bladder cancer treatment].
    Beardo Villar P; Gamaza Martínez R; Gavira Moreno R
    Farm Hosp; 2014 May; 38(3):249-51. PubMed ID: 24951911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
    Cao M; Ma CK; Ma J; Chen HG; Xue W
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):385-7. PubMed ID: 21875472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
    Karavana SY; Şenyiğit ZA; Çalışkan Ç; Sevin G; Özdemir Dİ; Erzurumlu Y; Şen S; Baloğlu E
    Drug Des Devel Ther; 2018; 12():1959-1975. PubMed ID: 29997433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative chemotherapy: when to use it, what to use, and why.
    Johnson DC; Pruthi RS; Woods ME
    Urol Clin North Am; 2013 May; 40(2):183-95. PubMed ID: 23540777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical therapy for superficial cancer: need for more options.
    Crawford ED
    J Clin Oncol; 2002 Aug; 20(15):3185-6. PubMed ID: 12149286
    [No Abstract]   [Full Text] [Related]  

  • 10. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder.
    Campodonico F; Maffezzini M
    Urology; 2005 Nov; 66(5):1141-2; author reply 1142. PubMed ID: 16286156
    [No Abstract]   [Full Text] [Related]  

  • 11. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
    Nativ O; Dalal E; Laufer M; Sabo E; Aronson M
    Urology; 2004 Oct; 64(4):845-8. PubMed ID: 15491745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer.
    Campodonico F; Mattioli F; Manfredi V; Capponi G; Pasquini P; Martelli A; Maffezzini M
    Anticancer Res; 2007; 27(2):1179-83. PubMed ID: 17465260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
    Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
    J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin in superficial bladder cancer: a preliminary study.
    Cho DY; Bae JH; Moon DG; Cheon J; Lee JG; Kim JJ; Yoon DK; Park HS
    J Int Med Res; 2009; 37(6):1823-30. PubMed ID: 20146880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actual experience and future development of gemcitabine in superficial bladder cancer.
    Gontero P; Frea B
    Ann Oncol; 2006 May; 17 Suppl 5():v123-8. PubMed ID: 16807439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.
    Mattioli F; Curotto A; Manfredi V; Gosmar M; Garbero C; Ambruosi C; Carmignani G; Martelli A
    Anticancer Res; 2005; 25(3c):2493-6. PubMed ID: 16080482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
    Serretta V; Galuffo A; Pavone C; Allegro R; Pavone-MacAluso M
    Urology; 2005 Jan; 65(1):65-9. PubMed ID: 15667865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability.
    Campodonico F; Canepa G; Capponi G; Bozzo L; Maffezzini M
    Anticancer Res; 2005; 25(3c):2381-4. PubMed ID: 16080464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gemcitabine: Applications and perspectives].
    Tumori; 1997; 83(5):877-80. PubMed ID: 9446252
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence of a clinically significant interaction between warfarin and intravesical gemcitabine.
    Kurtzhalts K; Gee ME; Feuz L; Krajewski KC
    Am J Health Syst Pharm; 2016 Oct; 73(19):1508-11. PubMed ID: 27646812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.